posted
Operational Plan set forth by BMSN (Regen):
Month 1-2: Assembly of Team. Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. - DONE (See post# 5463)
Month 1-4: In-licensing of Intellectual Property. The Company having already assessed over 20,000 issued patents and having compiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses on issued patents that have already passed preclinical studies but are not under clinical development.- DONE
SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. Source: http://finance.yahoo.com/news/bio-matrix-scientific-groups-regen-123000589.html
Month 3-6: Interaction with Regulatory Agencies. Regen intends to develop data packages for each of the technologies and initiate interaction with Regulatory Agencies such as the FDA for initiation of trials.- DONE (Clinartis!) Source: http://finance.yahoo.com/news/bio-matrix-regen-biopharma-unit-123000524.html
Month 6-18: Clinical Implementation. Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy. - Up Next!
According to David Koos, Chairman & CEO of Bio-Matrix, “HemaXellerate™ may provide an ideal therapeutic for bone marrow failure based upon: (1) regulating secretion of cytokines as biologically needed; (2) producing long-term, localized growth factors that alleviate the need for drugs; and (3) actively repairing the blood producing stem cell environment.”
A spokesperson for the Company said Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014. http://www.prweb.com/releases/2012/10/prweb9972993.htm
Month 18-24: Exit. It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline. - $$ $Patience Makes Bank$$$$
As I've mentioned before, it seems as though they are actually ahead of schedule and have BIG aspirations for the NEAR future. IMHO
$$ $Long and Strong...GO BMSN$$$$
pennybuilder
posted
Doing well today, 10X more buys then sells.
posted ![[Big Grin]](biggrin.gif)